Aligos Therapeutics, Inc. (NASDAQ: ALGS) enters 2026 with several important clinical catalysts ahead. The company is developing pevifoscorvir (ALG-000184), a capsid modulator designed to serve as a backbone therapy in future hepatitis B combination regimens.
If upcoming data confirm durability and safety, pevifoscorvir could help shift treatment strategies toward functional cure approaches rather than long-term viral suppression.
B-SUPREME Interim Updates Expected in 2026
The Phase 2 B-SUPREME trial remains on track. The first interim update for HBeAg- patients is expected in April or May 2026. A second interim analysis for HBeAg+ patients is anticipated in the second half of 2026.
These interim analyses will focus on safety and directional signals rather than full efficacy data. However, the updates should indicate whether pevifoscorvir performs in line with standard nucleos(t)ide analog therapies on viral suppression and tolerability.
Full topline data from the B-SUPREME study are expected in 2027.
EASL Durability Data Could Be a Key Catalyst
Meanwhile, investor attention is turning to durability data expected at the upcoming EASL conference.
Researchers will present follow-up results from a Phase 1 study examining whether viral suppression continues after treatment stops. Early observations showed encouraging signals. HBV DNA and RNA levels remained well below baseline, and investigators did not observe meaningful antigen rebound.
These findings suggest pevifoscorvir may help reduce the transcriptionally active viral reservoir that has historically made hepatitis B difficult to cure. If follow-up data confirm durable suppression off therapy, the program could gain stronger support as part of functional cure regimens.
Building a Potential Combination Strategy
At the same time, Aligos is advancing ALG-170675, an antisense oligonucleotide candidate, into GLP toxicology studies.
The company aims to identify a best-in-class ASO targeting hepatitis B. Management believes combining an ASO with pevifoscorvir could improve functional cure rates. In addition, a wholly owned combination strategy could strengthen the company’s negotiating position in future partnership discussions.
Cash Position and Development Timeline
Aligos reported $77.8 million in cash, cash equivalents, and restricted cash at the end of 2025. Current resources are expected to support operations into the third quarter of 2026.
As a result, the company will likely need additional capital or a strategic partnership before B-SUPREME topline data arrive in 2027.
Nevertheless, the upcoming interim analyses, durability data, and ASO progress should provide investors with a clearer view of pevifoscorvir’s potential role in next-generation hepatitis B treatment strategies.
The post Aligos Therapeutics: Durability Data Could Strengthen the Case for a Disease-Modifying HBV Backbone appeared first on PRISM MarketView.